What a new review says about incretin therapies in menopause

A review published in Maturitas looks at how incretin-based therapies are being used by midlife and postmenopausal women. This is a synthesis of existing research, not a new clinical trial. The authors pull together findings from pivotal studies and post hoc analyses to describe what is known, and just as importantly, what is not.

The therapies in question are GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide. The review is in humans, drawing on trial data. Its goal is to distinguish evidence gathered specifically in menopausal women from evidence extrapolated from wider populations.

Why menopause changes the picture

The authors note that the menopause transition brings meaningful shifts in body composition. These include more central fat, along with accelerated loss of muscle and bone. Those changes raise a woman's midlife risk of obesity and the cardiometabolic problems that can follow.

Against that backdrop, incretin-based therapies have become widely used for obesity. The review describes them as highly effective pharmacotherapies in that context, which is why researchers are asking how they perform specifically for women at this stage of life.

What the review reported

According to post hoc analyses of major trials, weight-loss efficacy appeared preserved across reproductive stages. The authors report that postmenopausal women achieved reductions in total body weight, waist circumference, and cardiometabolic risk factors comparable to those seen in premenopausal women.

The same weight loss, however, raises a specific concern. Postmenopausal women already experience declines in muscle and bone tied to estrogen deficiency, and the review flags that weight loss may add to those declines.

The body composition question

Current evidence, as the review summarizes it, suggests reductions in lean mass are generally proportional to how much weight is lost. These reductions were often accompanied by improved patient-reported physical function. That nuance matters, and the authors are careful about it.

Lean mass is not the same as skeletal muscle function. The review points out that few trials measured muscle strength or objective physical performance as primary outcomes. Findings on bone mineral density and fracture risk remained inconsistent across studies.

What this does and does not establish

This review establishes a current map of the evidence. It describes reported weight and cardiometabolic findings in menopausal women, and it identifies where conclusions rest on menopause-specific data versus extrapolation from other groups. It does not prove outcomes for any individual, and it does not resolve the open questions about muscle strength, physical performance, bone density, or fracture risk.

One honest limitation

The authors themselves highlight gaps in the evidence base. Much of what is known about musculoskeletal effects comes from measures of lean mass rather than tested muscle function, and the bone and fracture data do not line up neatly across studies. The review calls for a menopause-specific approach, including attention to nutrition, exercise, and musculoskeletal monitoring, which signals that important questions are still unsettled.

If you are considering care

Live Vital offers tirzepatide and semaglutide, both named or categorized among the therapies this review discusses. These are physician-prescribed and not retail products. A clinician determines whether any therapy is appropriate, and a physician decides on specifics after a medical intake.

This article is general information, not medical advice. If you want to discuss your own situation, treatment requires a medical intake and physician approval at get started, or you can book a free consult at consult. A prescription is never guaranteed.